The Conversation (0)
Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and nine months ended September 30, 2022.
Operational highlights (all dollar amounts are USD):
- Net revenues attributable to the Company's core business for the quarter ended September 30, 2022 were $35.8 million, a new Company record, and an increase of $7.9 million, or 28%, over core net revenues reported for the comparable quarter ended September 30, 2021. This represents 7% sequential growth in core revenue over the quarter ended June 30, 2022.
- Through September 30, 2022, the Company has repurchased and cancelled 1,673,620 common shares under the share repurchase program at a cost of $8.9 million, representing an average buyback price of $5.29 per share.
- The Company grew its ventilator patient count to 9,127, an 11% increase over the September 30, 2021 ventilator patient count, representing the highest year-over-year growth rate since the beginning of the COVID-19 pandemic.
- Adjusted EBITDA for the quarter ended September 30, 2022 totaled $7.0 million and Adjusted EBITDA for the nine months ended September 30, 2022 totaled $20.7 million. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.
- The Company had a cash balance of $21.5 million at September 30, 2022 ($28.4 million at December 31, 2021) and an overall working capital balance of $22.3 million at September 30, 2022 ($29.5 million at December 31, 2021). Total long-term debt as of September 30, 2022 was $4.2 million ($4.3 million at December 31, 2021).
- The Company expects to generate net revenues of approximately $37.1 million to $38.1 million during the fourth quarter of 2022.
"Our impressive third quarter financial results reflect robust growth and the team's disciplined execution of strategy," said Casey Hoyt, Viemed's CEO. "The momentum behind patient and service expansion continues to exceed expectations and we have successfully reversed margin compression in EBITDA. Looking forward, our inflation-adjusted reimbursement environment combined with tactical cost containment initiatives have the Company incredibly well positioned to outperform during the upcoming business cycle."
Conference Call Details
The Company will host a conference call to discuss second quarter results on Wednesday, November 2, 2022 at 11:00 a.m. ET.
Interested parties may participate in the call by dialing:
877-407-6176 (US Toll-Free)
201-689-8451 (International)
Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=cVEbVBdL
Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen Akselrod
Bristol Capital
905-326-1888
glen@bristolir.com
Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
investorinfo@viemed.com
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the fourth quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company's novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers and the recall of certain Royal Philips BiPAP and CPAP devices and ventilators that we distribute and sell; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of U.S. Dollars, except share amounts)
(Unaudited)
| At September 30, 2022 | At December 31, 2021 | ||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 21,478 | $ | 28,408 | |||
| Accounts receivable, net of allowance for doubtful accounts of $8,516 and $7,031 at September 30, 2022 and December 31, 2021, respectively | 14,982 | 12,823 | |||||
| Inventory, net of inventory reserve of $0 and $1,418 at September 30, 2022 and December 31, 2021, respectively | 3,178 | 2,457 | |||||
| Income tax receivable | 91 | 1,893 | |||||
| Prepaid expenses and other assets | 3,135 | 1,729 | |||||
| Total current assets | $ | 42,864 | $ | 47,310 | |||
| Long-term assets | |||||||
| Property and equipment, net | 68,109 | 62,846 | |||||
| Equity investments | 2,220 | 2,157 | |||||
| Deferred tax asset | 3,925 | 4,787 | |||||
| Other long-term assets | 2,301 | 862 | |||||
| Total long-term assets | $ | 76,555 | $ | 70,652 | |||
| TOTAL ASSETS | $ | 119,419 | $ | 117,962 | |||
| LIABILITIES | |||||||
| Current liabilities | |||||||
| Trade payables | $ | 3,737 | $ | 3,239 | |||
| Deferred revenue | 4,645 | 3,753 | |||||
| Accrued liabilities | 11,789 | 8,875 | |||||
| Current portion of lease liabilities | 220 | 464 | |||||
| Current portion of long-term debt | 165 | 1,480 | |||||
| Total current liabilities | $ | 20,556 | $ | 17,811 | |||
| Long-term liabilities | |||||||
| Accrued liabilities | 562 | 757 | |||||
| Long-term lease liabilities | 236 | 268 | |||||
| Long-term debt | 4,156 | 4,306 | |||||
| Total long-term liabilities | $ | 4,954 | $ | 5,331 | |||
| TOTAL LIABILITIES | $ | 25,510 | $ | 23,142 | |||
| Commitments and Contingencies | — | — | |||||
| SHAREHOLDERS' EQUITY | |||||||
| Common stock - No par value: unlimited authorized; 38,102,547 and 39,640,388 issued and outstanding as of September 30, 2022 and December 31, 2021, respectively | 14,927 | 14,014 | |||||
| Additional paid-in capital | 10,808 | 7,749 | |||||
| Accumulated other comprehensive loss | 56 | (278 | ) | ||||
| Retained earnings | 68,118 | 73,335 | |||||
| TOTAL SHAREHOLDERS' EQUITY | $ | 93,909 | $ | 94,820 | |||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 119,419 | $ | 117,962 | |||
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Revenue | $ | 35,759 | $ | 29,285 | $ | 101,324 | $ | 85,100 | |||||||
| Cost of revenue | 14,108 | 10,904 | 39,540 | 31,352 | |||||||||||
| Gross profit | $ | 21,651 | $ | 18,381 | $ | 61,784 | $ | 53,748 | |||||||
| Operating expenses | |||||||||||||||
| Selling, general and administrative | 17,677 | 13,260 | 50,989 | 40,653 | |||||||||||
| Research and development | 670 | 576 | 1,974 | 1,498 | |||||||||||
| Stock-based compensation | 1,309 | 1,302 | 3,885 | 3,845 | |||||||||||
| Depreciation | 291 | 211 | 771 | 618 | |||||||||||
| Loss on disposal of property and equipment | 292 | 145 | 168 | 304 | |||||||||||
| Other expense (income) | (57 | ) | (32 | ) | (721 | ) | (85 | ) | |||||||
| Income from operations | $ | 1,469 | $ | 2,919 | $ | 4,718 | $ | 6,915 | |||||||
| Non-operating income and expenses | |||||||||||||||
| Income from equity method investments | 84 | 331 | 853 | 782 | |||||||||||
| Interest expense, net of interest income | (42 | ) | (75 | ) | (165 | ) | (249 | ) | |||||||
| Net income before taxes | 1,511 | 3,175 | 5,406 | 7,448 | |||||||||||
| Provision for income taxes | 456 | 1,386 | 1,622 | 2,409 | |||||||||||
| Net income | $ | 1,055 | $ | 1,789 | $ | 3,784 | $ | 5,039 | |||||||
| Other comprehensive income | |||||||||||||||
| Change in unrealized gain/loss on derivative instruments, net of tax | 112 | 21 | 334 | 121 | |||||||||||
| Other comprehensive income | $ | 112 | $ | 21 | $ | 334 | $ | 121 | |||||||
| Comprehensive income | $ | 1,167 | $ | 1,810 | $ | 4,118 | $ | 5,160 | |||||||
| Net income per share | |||||||||||||||
| Basic | $ | 0.03 | $ | 0.05 | $ | 0.10 | $ | 0.13 | |||||||
| Diluted | $ | 0.03 | $ | 0.04 | $ | 0.09 | $ | 0.12 | |||||||
| Weighted average number of common shares outstanding: | |||||||||||||||
| Basic | 38,232,788 | 39,607,540 | 38,870,949 | 39,442,088 | |||||||||||
| Diluted | 39,583,438 | 40,659,353 | 39,852,297 | 40,716,747 | |||||||||||
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of U.S. Dollars)
(Unaudited)
| Nine Months Ended September 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 3,784 | $ | 5,039 | ||||
| Adjustments for: | ||||||||
| Depreciation | 11,257 | 8,192 | ||||||
| Provision for uncollectible accounts | 7,811 | 5,250 | ||||||
| Change in inventory reserve | (1,418 | ) | (116 | ) | ||||
| Share-based compensation expense | 3,885 | 3,845 | ||||||
| Distributions of earnings received from equity method investments | 931 | 172 | ||||||
| Income from equity method investments | (853 | ) | (782 | ) | ||||
| Loss on disposal of property and equipment | 168 | 304 | ||||||
| Deferred income tax expense | 745 | 2,410 | ||||||
| Net change in working capital | ||||||||
| Increase in accounts receivable | (9,970 | ) | (5,573 | ) | ||||
| Decrease (increase) in inventory | 697 | (196 | ) | |||||
| Increase in prepaid expenses and other assets | (2,870 | ) | (2,259 | ) | ||||
| Increase in trade payables | 33 | 2,638 | ||||||
| Increase in deferred revenue | 892 | 386 | ||||||
| Increase (decrease) in accrued liabilities | 3,170 | (3,711 | ) | |||||
| Change in income tax payable/receivable | 1,802 | (1,760 | ) | |||||
| Net cash provided by operating activities | $ | 20,064 | $ | 13,839 | ||||
| Cash flows from investing activities | ||||||||
| Purchase of property and equipment | (17,326 | ) | (13,080 | ) | ||||
| Investment in equity investments | (141 | ) | (599 | ) | ||||
| Proceeds from sale of property and equipment | 869 | 496 | ||||||
| Net cash used in investing activities | $ | (16,598 | ) | $ | (13,183 | ) | ||
| Cash flows from financing activities | ||||||||
| Proceeds from exercise of options | 87 | 112 | ||||||
| Principal payments on notes payable | (119 | ) | (113 | ) | ||||
| Principal payments on term note | (1,321 | ) | (1,255 | ) | ||||
| Shares redeemed to pay income tax | (143 | ) | (1,434 | ) | ||||
| Shares repurchased under the share repurchase program | (8,858 | ) | — | |||||
| Repayments of lease liabilities | (42 | ) | (2,080 | ) | ||||
| Net cash used in financing activities | $ | (10,396 | ) | $ | (4,770 | ) | ||
| Net decrease in cash and cash equivalents | (6,930 | ) | (4,114 | ) | ||||
| Cash and cash equivalents at beginning of year | 28,408 | 30,981 | ||||||
| Cash and cash equivalents at end of period | $ | 21,478 | $ | 26,867 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid during the period for interest | $ | 185 | $ | 278 | ||||
| Cash paid (received) during the period for income taxes, net of refunds | $ | (920 | ) | $ | 1,760 | |||
| Supplemental disclosures of non-cash transactions | ||||||||
| Net non-cash changes to finance leases | $ | — | $ | 42 | ||||
| Net non-cash changes to operating leases | $ | 150 | $ | 372 | ||||
Non-GAAP Financial Measures
This press release refers to "Adjusted EBITDA" which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation, and stock-based compensation. Management believes Adjusted EBITDA provides helpful information with respect to the Company's operating performance as viewed by management, including a view of the Company's business that is not dependent on the impact of the Company's capitalization structure and items that are not part of the Company's day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company's operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company's employees, (iii) for planning purposes, including the preparation of the Company's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating performance in the same manner as management. The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
VIEMED HEALTHCARE, INC.
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA
(Expressed in thousands of U.S. Dollars)
(Unaudited)
| For the quarter ended | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | |||||||||
| Net Income | $ | 1,055 | $ | 967 | $ | 1,762 | $ | 4,087 | $ | 1,789 | $ | 1,566 | $ | 1,684 | $ | 5,071 | |
| Add back: | |||||||||||||||||
| Depreciation | 4,120 | 3,740 | 3,397 | 3,120 | 2,867 | 2,716 | 2,609 | 2,835 | |||||||||
| Interest expense | 42 | 59 | 64 | 69 | 75 | 83 | 91 | 100 | |||||||||
| Stock-based compensation | 1,309 | 1,271 | 1,305 | 1,305 | 1,302 | 1,236 | 1,307 | 1,301 | |||||||||
| Income tax expense (benefit) | 456 | 421 | 745 | 968 | 1,386 | 1,246 | (223 | ) | 151 | ||||||||
| Adjusted EBITDA | $ | 6,982 | $ | 6,458 | $ | 7,273 | $ | 9,549 | $ | 7,419 | $ | 6,847 | $ | 5,468 | $ | 9,458 | |
| Three Months Ended September 30, 2022 | Nine Months Ended September 30, 2022 | |||||
| Net Income | $ | 1,055 | $ | 3,784 | ||
| Add back: | ||||||
| Depreciation | 4,120 | 11,257 | ||||
| Interest expense | 42 | 165 | ||||
| Stock-based compensation | 1,309 | 3,885 | ||||
| Income tax expense (benefit) | 456 | 1,622 | ||||
| Adjusted EBITDA | $ | 6,982 | $ | 20,713 | ||
Use of Non-GAAP Financial Measures
Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. It is not a measurement of the Company's financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company's operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company's industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
VIEMED HEALTHCARE, INC.
Key Financial and Operational Information
(Expressed in thousands of U.S. Dollars, except vent patients)
(Unaudited)
| For the quarter ended | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | ||||||||||||||||
| Financial Information: | ||||||||||||||||||||||||
| Revenue | $ | 35,759 | $ | 33,310 | $ | 32,255 | $ | 31,962 | $ | 29,285 | $ | 27,399 | $ | 28,416 | $ | 31,202 | ||||||||
| Gross Profit | $ | 21,651 | $ | 20,390 | $ | 19,743 | $ | 19,662 | $ | 18,381 | $ | 17,625 | $ | 17,742 | $ | 19,178 | ||||||||
| Gross Profit % | 61 | % | 61 | % | 61 | % | 62 | % | 63 | % | 64 | % | 62 | % | 61 | % | ||||||||
| Net Income | $ | 1,055 | $ | 967 | $ | 1,762 | $ | 4,087 | $ | 1,789 | $ | 1,566 | $ | 1,684 | $ | 5,071 | ||||||||
| Cash (As of) | $ | 21,478 | $ | 21,922 | $ | 29,248 | $ | 28,408 | $ | 26,867 | $ | 31,151 | $ | 31,097 | $ | 30,981 | ||||||||
| Total Assets (As of) | $ | 119,419 | $ | 115,904 | $ | 119,007 | $ | 117,962 | $ | 115,486 | $ | 111,014 | $ | 113,001 | $ | 112,560 | ||||||||
| Adjusted EBITDA (1) | $ | 6,982 | $ | 6,458 | $ | 7,273 | $ | 9,549 | $ | 7,419 | $ | 6,847 | $ | 5,468 | $ | 9,458 | ||||||||
| Operational Information: | ||||||||||||||||||||||||
| Vent Patients (2) | 9,127 | 8,837 | 8,434 | 8,405 | 8,200 | 8,103 | 7,733 | 7,892 | ||||||||||||||||
(1) Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.
(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.
